A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell-Lung Cancer

被引：0

作者：

Harada, D. ^{[1
]}

Kozuki, T. ^{[1
]}

Nogami, N. ^{[1
]}

Hotta, K. ^{[2
]}

Aoe, K. ^{[3
]}

Ohashi, K. ^{[2
]}

Ninomiya, K. ^{[2
]}

Hirata, T. ^{[4
]}

Hinotsu, S. ^{[5
]}

Toyooka, S. ^{[6
]}

Kiura, K. ^{[2
]}

机构：

[1] Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan

[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[3] Yamaguchi Ube Med Ctr, Dept Med Oncol, Ube, Yamaguchi, Japan

[4] Kure Med Ctr, Dept Med Oncol, Kure, Japan

[5] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[6] Okayama Univ, Grad Sch Med, Gen Thorac Surg & Breast & Endocrinol Surg, Okayama, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

NSCLC; HER2; T-DM1;

D O I：

10.1016/j.jtho.2017.09.511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 07.11

引用

页码：S1829 / S1829

页数：1

共 50 条

[41] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
Mamounas, Eleftherios P.
Geyer, Charles E., Jr.
Huang, Chiun-Sheng
Mano, Max S.
Loibl, Sibylle
Untch, Michael
Wolmark, Norman
Rastogi, Priya
Schneeweiss, Andreas
Redondo, Andres
Fischer, Hans H.
Jacot, William
Conlin, Alison K.
Arce-Salinas, Claudia
Wapnir, Irene L.
Jackisch, Christian
DiGiovanna, Michael P.
Fasching, Peter A.
Crown, John P.
Wuelfing, Pia
Shao, Zhimin
Caremoli, Elena Rota
Wu, Haiyan
Lam, Lisa H.
Tesarowski, David
Smitt, Melanie
Douthwaite, Hannah
Singel, Stina M.
von Minckwitz, Gunter
SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
[42] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
Lin, N. U.
Seah, D. S.
Gelman, R.
Desantis, S.
Mayer, E. L.
Isakoff, S.
DiPiro, P.
Krop, I. E.
Come, S. E.
Weckstein, D.
Winer, E. P.
Burstein, H. J.
BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
[43] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
Sliwkowski, Mark X.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[44] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
Thibault, C.
ONCOLOGIE, 2013, 15 (02) : 126 - 127
[45] A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer
Lucas Bayo-Calero, Juan
Mayordomo, Jose I.
Salnchez-Rovira, Pedro
Perez-Carrion, Ramon
Illaramendi, Jose J.
Garcia-bueno, Jose M.
Gonzalez-Flores, Encarnacion
Crespo, Carmen
Ramos-Vazquez, Manuel
Garcia-Palomo, Andres
Ruiz-Borrego, Manuel
de la Haba, Juan
Gomez-Bernal, Amalia
Yubero-Esteban, Alfonso
CLINICAL BREAST CANCER, 2008, 8 (03) : 264 - 268
[46] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
N. U. Lin
D. S. Seah
R. Gelman
S. Desantis
E. L. Mayer
S. Isakoff
P. DiPiro
I. E. Krop
S. E. Come
D. Weckstein
E. P. Winer
H. J. Burstein
Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
[47] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
不详
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
[48] Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
Burris, Howard A., III
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 807 - 819
[49] Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer
Watanabe, Junichiro
Ito, Yoshinori
Saeki, Toshiaki
Masuda, Norikazu
Takano, Toshimi
Takao, Shintaro
Nakagami, Kazuhiko
Tsugawa, Koichiro
Nakagawa, Shintaro
Kanatani, Kazumitsu
Nakayama, Takahiro
IN VIVO, 2017, 31 (03): : 493 - 500
[50] Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
Krop, Ian
Winer, Eric P.
CLINICAL CANCER RESEARCH, 2014, 20 (01) : 15 - 20

← 1 2 3 4 5 →